What does this research mean for the field?

In real-world clinical practice, rates of rivaroxaban-related major bleeding are relatively low, and the clinical outcomes are comparable to or potentially better than those associated with major vitamin K antagonist bleeding. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to investigate the rates, management, and outcomes of bleeding complications associated with rivaroxaban in everyday clinical practice.

May 24, 2014BloodOpen Access

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

View Full Paper

Ask AI

Bookmark

Why the study?

What are the rates, management, and outcomes of rivaroxaban-related bleeding in real-world daily care patients?

Population

1776 daily care patients receiving rivaroxaban for stroke prevention in atrial fibrillation or treatment of…

Design

Cohort

Authors

JBJan Beyer‐WestendorfVascular Medicine KFKati FörsterUniversity of Vienna SPSven PannachUniversity Hospital Carl Gustav Carus

Discussion

Member takes

Implication

Supports low major bleeding rates with rivaroxaban in real-world settings; extends prior evidence but leaves randomized comparisons open.

Key Points

This research aims to investigate the rates, management, and outcomes of bleeding complications associated with rivaroxaban in everyday clinical practice.
Utilized data from the Dresden NOAC registry involving 1776 patients on rivaroxaban.
Conducted a time-to-first-event analysis and an as-treated analysis to determine bleeding rates and outcomes.
Categorized bleeding events based on severity according to International Society on Thrombosis and Haemostasis definitions.
Reported 1082 bleeding events (42.9% of patients), with 6.1% classified as major bleeding.
100-patient-year rates of major bleeding were 3.1 for atrial fibrillation and 4.1 for venous thromboembolism.
Case fatality rates for bleeding leading to hospitalization were 5.1% at 30 days and 6.3% at 90 days.

Structured PICO

What are the rates, management, and outcomes of rivaroxaban-related bleeding in real-world daily care patients?

Population

1776 daily care patients receiving rivaroxaban for stroke prevention in atrial fibrillation or treatment of venous thromboembolism enrolled in the Dresden NOAC registry.

Intervention

Rivaroxaban

Outcome

Rates, management, and outcome of rivaroxaban-related bleedingsafety

In real-world practice, rivaroxaban-related major bleeding rates are relatively low and outcomes appear comparable to or better than historical vitamin K antagonist bleeding.

Cite This Study

Beyer‐Westendorf et al. (2014) studied this question.

synapsesocial.com/papers/6a1d49feba3016ff712f6251 https://doi.org/10.1182/blood-2014-03-563577

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider